Ribavirin for Hepatitis E Virus Infection After Organ Transplantation

Autor: Kamar, Nassim, Legrand-Abravanel, Florence, Behrendt, Patrick, Hofmann, Jörg, Pageaux, Georges Phillippe, Barbet, Christelle, Moal, Valerie, Couzi, Lionel, Horvatits, Thomas, de Man, Robert, Cassuto, Elisabeth, Elsharkawy, Ahmed, Riezebos-Brilman, Annelies, Scemla, Anne, Hillaire, Sophie, Donnelly, Mhairi, Radenne, Sylvie, Sayegh, Johnny, Garrouste, Cyril, Dumortier, Jérôme, Glowaki, François, Matignon, Marie, Coilly, Audrey, Figueres, Lucile, Mousson, Christiane, Minello, Anne, Dharancy, Sébastien, Rerolle, Jean Philippe, Lebray, Pascal, Etienne, Isabelle, Perrin, Peggy, Choi, Mira, Olivier, Marion, Izopet, Jacques, Bellière, J, Cointault, O., del Bello, Arnaud, Espostio, L, Hebral, A, Lavayssière, L, Lhomme, S, Mansuy, J, Wedemeyer, H, Nickel, P, Bismuth, M., Stefic, K, Buchler, M., D’alteroche, L, Colson, P., Bufton, S, Ramière, C, Trimoulet, P., Pischke, S, Todesco, E, Sberro Soussan, R, Legendre, C, Mallet, V., Johannessen, I, Simpson, K

Publikováno v: Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(5), 1204-1211. Oxford University Press
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
United States
Clinical Infectious Diseases, 71(5), 1204-1211. Oxford University Press
Clinical Infectious Diseases, Oxford University Press (OUP), 2019, ⟨10.1093/cid/ciz953⟩
Clinical Infectious Diseases, 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩

Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9291b965e91f3ecf369fd895a0047810
https://hal-amu.archives-ouvertes.fr/hal-02465266

No evidence of occult hepatitis C or E virus infections in liver‐transplant patients with sustained virological response after therapy with direct acting agents

Autor: Sébastien Lhomme, Laurent Alric, Laurence Lavayssière, Florence Abravanel, Jacques Izopet, Nassim Kamar, Arnaud Del Bello, Julie Belliere

Publikováno v: Transplant Infectious Disease
Transplant Infectious Disease, Wiley, 2019, 21 (4), ⟨10.1111/tid.13093⟩
Transplant Infectious Disease, 2019, 21 (4), pp.e13093. ⟨10.1111/tid.13093⟩

International audience; Background and aims: It has been recently suggested that occult hepatitis C virus (HCV) infection and hepatitis E virus (HEV) reactivation might occur after direct acting antiviral agent-induced (DAA-induced) sustained virolog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c27634420a94a8dd91ada9121bae4669
https://doi.org/10.1111/tid.13093

Pyrimethamine inhibits rabies virus replication in vitro

Autor: Hervé Bourhy, Florence Larrous, Dirk Jochmans, Youcef Ben-Khalifa, Johan Neyts, Sophie Rogée

Publikováno v: Antiviral Research
Antiviral Research, Elsevier Masson, 2019, 161, pp.1-9. ⟨10.1016/j.antiviral.2018.10.016⟩
Antiviral Research, 2019, 161, pp.1-9. ⟨10.1016/j.antiviral.2018.10.016⟩

Rabies virus transmits from animals to humans and causes encephalitis. Every year more than 15 million people receive a post exposure prophylaxis (PEP) treatment that is highly effective in the prevention of rabies disease. However, when clinical sym

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318c5700a008ecf171aece4113c8f35a
https://lirias.kuleuven.be/handle/123456789/629293

Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients

Autor: Nassim Kamar, Laurence Lavayssière, Anne Laure Hebral, Olivier Marion, Jacques Izopet, Olivier Cointault, Laure Esposito, Sébastien Lhomme, David Ribes, Arnaud Del Bello, Florence Abravanel

Publikováno v: Journal of Hepatology
Journal of Hepatology, 2019, 70 (1), pp.206-214. ⟨10.1016/j.jhep.2018.09.011⟩

International audience; Hepatitis E virus genotype 3 (HEV3) and 4 (HEV4) can progress to chronic hepatitis in immunosuppressed patients.1 Ribavirin therapy has been shown to be efficient for treating chronic HEV infection in solid-organ-transplant re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08fefcd9d62ea9f71744877fdd80ee07
https://ut3-toulouseinp.hal.science/hal-03602075

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

Autor: Christian Trepo, Michael P. Manns, David Wright, Jose Luis Calleja, Peter W. White, Chan-Loi Yong, Stanislas Pol, George Kukolj, Jerry O. Stern, Marc Bourlière, Maurizio Bonacini, Thomas Berg, Wulf Otto Boecher, Yves Benhamou, Gerhard G. Steinmann, Joe Scherer

Publikováno v: Journal of Hepatology
Journal of Hepatology, Elsevier, 2011, 54 (6), pp.1114-22. ⟨10.1016/j.jhep.2010.08.040⟩
Journal of Hepatology, Elsevier, 2011, 54 (6), pp.1114-22. 〈10.1016/j.jhep.2010.08.040〉

International audience; BACKGROUND & AIMS: BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in chronic HCV genotype-1 patients. METHODS: Thirty-four treatment-na�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::947da88215c342d73ca0ef790ae3bfd6
https://doi.org/10.1016/j.jhep.2010.08.040